No improvement seen in HIV-associated lymphoma survival during the antiretroviral therapy era
Stable survival rates were observed for HIV-associated lymphoma patients during the antiretroviral therapy (ART) era in the US, according to a new study published in the Journal of the National Cancer Institute. Studies have shown that HIV infection increases the risk of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) and that incidence for many lymphoma types has not decreased in the ART era. Furthermore, lymphoma is the most frequent cancer-related cause of death among HIV-infected persons... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 30, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Mapping Link Between Blood Cancer, Industrial Pollutant in Georgia
Benzene appears to raise risk of non-Hodgkin lymphoma, researchers say (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - July 30, 2013 Category: Cancer & Oncology Source Type: news

Living near industrial plant may raise risk of non-Hodgkin lymphoma
Cancer risk dropped 0.31 percent for every mile further away person lived from benzene-producing facility in Georgia (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 29, 2013 Category: Consumer Health News Source Type: news

Benzene Exposure Linked to Increased Rate of NHLBenzene Exposure Linked to Increased Rate of NHL
Populations living close to sites that release benzene into the environment have higher rates of non-Hodgkin's lymphoma (NHL), suggesting an association. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mapping Link Between Blood Cancer, Industrial Pollutant in Georgia
Benzene appears to raise risk of non-Hodgkin lymphoma, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 29, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Family Medicine, Oncology, News, Source Type: news

Higher Cancer Incidences Found in Regions Near Refineries and Plants that Release Benzene
The incidence of a particular type of blood cancer is significantly higher in regions near facilities that release the chemical benzene into the environment. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. This and other studies like it will be critical to identifying and enacting public health policies to decrease or prevent cancer. Non-Hodgkin lymphoma has been on the rise over the past few decades as industrial production in the United States has expanded... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 29, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

GAUGUIN: Higher Obinutuzumab Dose Shows Promise in Non-Hodgkin Lymphoma
The phase II portion of the GAUGUIN study found promising activity with the anti-CD20 antibody obinutuzumab in patients with relapsed or refractory indolent NHL. (Source: Cancer Network)
Source: Cancer Network - July 22, 2013 Category: Cancer & Oncology Source Type: news

Oil Worker Abandons Radiation Theory But Defends Benzene Claims
NEW ORLEANS - An oil and gas field worker alleging injury from exposure to benzene opposes partial summary judgment but acknowledges in a June 18 brief in Louisiana federal court that he has abandoned a theory that radioactivity in the petroleum distillates he handled contributed to his non-Hodgkin's lymphoma (Chris Cologne, et uxor v. Shell Oil Co., et al., No. 12-735, E.D. La.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 4, 2013 Category: Medical Law Source Type: news

Second Draft NICE Guidance For Aggressive Non-Hodgkin Lymphoma Treatment, PIXUVRI® (Pixantrone)
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) have announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom, issued a second draft guidance on the use of PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Two Studies Reveal Important Genetic Insights Into The Development Of Non-Hodgkin Lymphoma (NHL)
Scientists at the Genome Institute of Singapore (GIS) recently led in two studies that revealed important genetic insights into the development of non-Hodgkin lymphoma (NHL). NHLs are some of the most common blood cancers and include any kind of lymphoma1 except Hodgkin's lymphomas. Study 1: discovered novel inheritable gene variant that increases risk of blood cancer in Asians In the first study, reported in the prestigious scientific journal Nature Genetics, the scientists discovered an inheritable gene variant which increases the risk of non-Hodgkin lymphoma (NHL) in Asians... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 2, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Non-Hodgkin Lymphoma Survival Predicted By Dose Analysis
Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art 3D imaging could lead to more personalized and effective treatments to improve patients' chances of living longer without progression of their cancer, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 13, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

More Radiation, Less Progression in Non-Hodgkin's LymphomaMore Radiation, Less Progression in Non-Hodgkin's Lymphoma
Patients receiving I-131 radioimmunotherapy who received more than 200 cGy to tumors had significantly longer progression-free survival. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 10, 2013 Category: Consumer Health News Tags: Radiology News Source Type: news

New clinical trial has given my dad hope of beating blood cancer
WHEN 44-year-old Jason Hayden’s father Ron, 70, was diagnosed with non-Hodgkin lymphoma last year the family were distraught. (Source: Daily Express - Health)
Source: Daily Express - Health - June 4, 2013 Category: Consumer Health News Source Type: news

Promising data from the Bcl-2 inhibitor GDC-0199/ABT-199 in hematology presented at ASCO
Late stage development underway in chronic lymphocytic leukemia. Roche today announced promising phase 1 data from a study of GDC-0199/ABT-199, also known as RG7601, in people with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Data were presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Relapsed cancer refers to a cancer that returns after a period of remission while refractory cancer refers to a cancer that is no longer responding to treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2013 Category: Pharmaceuticals Source Type: news

Survival from non-Hodgkin lymphoma doubles since 1970s
Better treatments and diagnosis boost survival, says reportRelated items from OnMedicaChild leukaemia cure rate has increasedCancer survival rates not improved much in a decade Combined treatment works best for anal cancerCancer survivors more prone to stress than othersFree prescriptions for cancer patients (Source: OnMedica Latest News)
Source: OnMedica Latest News - May 24, 2013 Category: UK Health Source Type: news

Pfizer ends inotuzumab ozogamicin Phase 3 non-Hodgkin lymphoma study
Pfizer has stopped the Phase 3 randomised, open-label study (B1931008) of inotuzumab ozogamicin in relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL). (Source: Drug Development Technology)
Source: Drug Development Technology - May 21, 2013 Category: Pharmaceuticals Source Type: news

Pfizer halts study of lymphoma drug unlikely to help survival
(Reuters) - Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival. (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Radiotherapy Is NOT Essential to Cure Diffuse Large B-Cell Non-Hodgkin Lymphoma
DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease biology, and all future efforts to cure patients will require improved systemic therapy. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Breast Schwannoma With Diffuse Large B-Cell LymphomaBreast Schwannoma With Diffuse Large B-Cell Lymphoma
Was there a connection between this patient's non-Hodgkin's lymphoma and her breast mass? Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Researchers Say NSAIDs Can Boost Stem Cells For Transplants For Cancer Patients
Scientists say that non-steroidal anti-inflammatory drugs may be a boon to doctors gathering stem cells for transplants to treat patients with blood or bone marrow cancers, including non-Hodgkin's lymphoma and multiple myeloma. The compounds, known as NSAIDs and which include aspirin, ibuprofen and other painkillers, increased the number of stem and progenitor cells harvested from the blood in animal testing and a small human study, according to work published online Wednesday in the journal Nature by a research team led by Indiana University School of Medicine scientists... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Stem Cell Research Source Type: news

Trends in Post-Treatment Leukemia
The risks of chemotherapy-related acute myeloid leukemia have changed significantly over the last 30 years, increasing in people treated for non-Hodgkin's lymphoma and decreasing in people treated for... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 28, 2013 Category: Cancer & Oncology Source Type: news

Treatment-Related AML Rises in Non-Hodgkin's Lymphoma
The risks of chemotherapy-related acute myeloid leukemia have changed significantly over the last 30 years, increasing in people treated for non-Hodgkin's lymphoma and decreasing in people treated for... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 26, 2013 Category: Cancer & Oncology Source Type: news

Bendamustine (Levact®) Plus Rituximab More Effective Than CHOP-R In Treating Patients With Indolent Non-Hodgkin Lymphoma And Mantle Cell Lymphoma
Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p Results from the StiL NHL-1 study published in The Lancet this week show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL).1 Median PFS for patients treated with B-R was 69... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Bendamustine data published in The Lancet
Results from the StiL NHL-1 study published in The Lancet show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab (CHOP-R), in newly diagnosed patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL). (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

Diffuse Large B-Cell Non-Hodgkin Lymphoma in the Very Elderly: Challenges and Solutions
In this review, we critically analyze clinical trials that were specifically designed for the very elderly, and we discuss the challenges encountered by investigators who are conducting studies in this patient population. We conclude by proposing an algorithm to help clinicians determine the optimal therapeutic strategy for treatment of DLBCL in very elderly patients. (Source: Cancer Network)
Source: Cancer Network - February 15, 2013 Category: Cancer & Oncology Source Type: news

After cancer, my real fight began
In January of 2011, at 25, I was diagnosed with non-Hodgkin's lymphoma. I went through four months of chemotherapy and eight weeks of radiation. (Source: CNN.com - Health)
Source: CNN.com - Health - January 31, 2013 Category: Consumer Health News Source Type: news

Cancer death rates are a third higher in men
The fact that men are more likely than women to both develop and die from cancer has been covered by most of the media today. The news is based on a report highlighting the excess cancer burden in men (both in terms of cases and deaths), and was produced by Cancer Research UK, the Men’s Health Forum and the National Cancer Intelligence Network. The results of the report were widely and accurately reported in the media. The report found that men are at significantly greater risk of both developing and dying from cancer, and the difference in risk increased further when breast and sex-specific cancers, for examp...
Source: NHS News Feed - January 29, 2013 Category: Consumer Health News Tags: Cancer QA articles Source Type: news

Non-Hodgkin Lymphoma
Prognostic Factors and Targetsseries:Cancer Drug Discovery and DevelopmentRecent developments in the therapy of non-Hodgkin lymphoma have improved response and survival rates in patients with these conditions. This book is focused on the biology, prognostic factors and novel targets of non-Hodgkin lymphoma. We believe that understanding the pathophysiology of non-Hodgkin lymphoma provides a mean to improve its risk-stratification and treatment. This book is intended ... (Source: Springer Biomedical Sciences titles)
Source: Springer Biomedical Sciences titles - January 26, 2013 Category: Biomedical Science Tags: Cancer Research Source Type: news

Five-Minute' Blood Cancer Injection Cuts Treatment Time By Two Hours
A new injection for blood cancer patients trialled at Southampton's teaching hospitals can deliver a two-hour dose of drugs in around five minutes. Patients diagnosed with follicular non-Hodgkin lymphoma (NHL), a disease that attacks one specific type of infection-fighting cell, previously had rituximab administered via an intravenous drip... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Patient Survival In Non-Hodgkins Lymphoma Predicted By Epigenomic Abnormalities
Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published in the journal PLOS Genetics shows that in cancer, not only can genes themselves go bad, but abnormal changes in the epigenetic mixing board can unfortunately change the expression of these genes. Researchers hope to play the role of sound engineers, controlling these harmful epigenomic changes to turn down cancer itself or perhaps sensitize cancers to existing drugs... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 13, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

PCR-Based Analysis of Rearranged Immunoglobulin or T-Cell Receptor Genes by GeneScan Analysis or Heteroduplex Analysis for Clonality Assessment in Lymphoma Diagnostics
The assessment of the presence of clonal lymphoproliferations via polymerase chain reaction (PCR)-based analysis of rearranged immunoglobulin (Ig) or T-cell receptor (TCR) genes is a valuable technique in the diagnosis of suspect lymphoproliferative disorders. Furthermore this technique is more and more used to evaluate dissemination of non-Hodgkin lymphoma and/or the presence of (minimal) residual disease. In this chapter we describe an integrated approach to assess clonality via analysis of Ig heavy chain (IGH), Ig kappa (IGK), TCR beta (TCRB), and TCR gamma (TCRG) gene rearrangements. The described PCR protocol is based...
Source: Springer protocols feed by Cancer Research - January 11, 2013 Category: Cancer & Oncology Source Type: news

Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
"Not only do we see more abnormal methylation in non-Hodgkin lymphoma patients than in healthy B-cell populations, but there are three distinct subtypes of the disease in the clinic, each more aggressive than the next. These three clinical trajectories of non-Hodgkins lymphoma were distinctly marked by their levels of abnormal methylation," says a CU Cancer Center investigator. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2013 Category: Science Source Type: news

Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
(University of Colorado Denver) "Not only do we see more abnormal methylation in non-Hodgkin lymphoma patients than in healthy B-cell populations, but there are three distinct subtypes of the disease in the clinic, each more aggressive than the next. These three clinical trajectories of non-Hodgkins lymphoma were distinctly marked by their levels of abnormal methylation," says a CU Cancer Center investigator. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 10, 2013 Category: Cancer & Oncology Source Type: news

TG Therapeutics commences TGR-1202 Phase I trial
TG Therapeutics has begun first-in-human, Phase I trial of TGR-1202 in patients suffering from hematologic malignancies such as relapsed or refractory Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Peripheral T-Cell Lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - January 9, 2013 Category: Pharmaceuticals Source Type: news

Unusual Analyst Upgrade & Endorsement for Cell Therapeutics (CTIC)
Cell Therapeutics, Inc. (NASDAQ: CTIC) is a controversial stock in the field of cancer and the company is still aiming for a 2012 debut market launch for its pixantrone drug candidate.  In the last couple of weeks it had reported more positive data and the FDA had earlier this year noted that pixantrone would need a review using a new panel of independent radiologists.  Pixantrone is to be a new treatment for non-Hodgkin Lymphoma.   This morning we saw a very unlikely and very unusual support or endorsement of Cell Therapeutics.  This came from Zacks Investment Research where the outfit was called The B...
Source: BioHealth Investor - October 13, 2011 Category: Pharmaceuticals Authors: 247admin Tags: analyst calls Cancer fda R&D Research CTIC Source Type: news

ADAO Lights a Candle for Workers' Memorial Day
On April 28, the Asbestos Disease and Awareness Organization (ADAO) will recognize Workers' Memorial Day through their Light a Candle program. The program encourages people to light a candle or do so through their website to honor loved ones who are fighting or have lost their fight against asbestos-related diseases. As of April 26 2011, over 11 million candles have been lit in a total of 243 countries. Each year, approximately 125 million workers are regularly exposed to asbestos. Asbestos has been directly linked to the development of malignant mesothelioma, an uncommon and aggressive cancer that attacks the lining of th...
Source: Asbestos and Mesothelioma News - April 26, 2011 Category: Environmental Health Authors: Michael Sedacca Tags: Asbestos Exposure & Bans Source Type: news

Van Andel Institute conducting cancer research in Asia
The Van Andel Research Institute will soon be conducting cancer research in Southeast Asia. It’s being called a ground breaking agreement. The $1.2 million, 3 year deal is funded by the National Cancer Center in Singapore. Scientists would study types of cancer that seem to be more prevalent among certain ethnic groups. The study will compare cancer in Caucasian patients verses cancer in Asian patients. For example, prostate cancer is more prevalent among white people. Liver cancer seems be more prevalent among Asians. WZZM 13 News got a glimpse inside the Van Andel Research Institute, where doctors say they ar...
Source: Kidney Cancer Association - November 1, 2007 Category: Urology & Nephrology Source Type: news

Van Andel Institute conducting cancer research in Asia
The Van Andel Research Institute will soon be conducting cancer research in Southeast Asia. It’s being called a ground breaking agreement. The $1.2 million, 3 year deal is funded by the National Cancer Center in Singapore. Scientists would study types of cancer that seem to be more prevalent among certain ethnic groups. The study will compare cancer in Caucasian patients verses cancer in Asian patients. For example, prostate cancer is more prevalent among white people. Liver cancer seems be more prevalent among Asians. WZZM 13 News got a glimpse inside the Van Andel Research Institute, where doctors say they are maki...
Source: Kidney Cancer Association - November 1, 2007 Category: Urology & Nephrology Source Type: news

NCCN to Present Guidelines in China
JENKINTOWN, Pa., February 21, 2007 — The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 of the world’s leading cancer centers, will present the Breast, Colorectal, Gastric, Non-Small Cell Lung and Non-Hodgkin`s Lymphoma (NHL) NCCN Clinical Practice Guidelines in Oncology in Beijing, Shanghai and Guangzhou, China. Over the course of five meetings in March and April, experts from NCCN Member Institutions and leading physicians in China will review and adapt these gui... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 21, 2007 Category: Cancer & Oncology Source Type: news

Utilization of Rituximab Therapy in Patients (pts) with Newly Diagnosed Follicular (FL) and Diffuse Large B Cell (DLCL) Non-Hodgkins Lymphoma (NHL) in the United States: An Analysis from the National Comprehensive Cancer Network (NCCN)
[1800] Utilization of Rituximab Therapy in Patients (pts) with Newly Diagnosed Follicular (FL) and Diffuse Large B Cell (DLCL) Non-Hodgkins Lymphoma (NHL) in the United States: An Analysis from the National Comprehensive Cancer Network (NCCN) [abstract]. NHL Outcomes Project [abstract]. American Society of Hematology: Session Type: Poster Session 912-I Jonathan W. Friedberg, Eva Lepisto, Maria Alma Rodriguez, Rebecca Ottensen, Ann S. LaCasce, Auayporn P. Nademanee, Michael Millenson, Myro... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 16, 2003 Category: Cancer & Oncology Source Type: news